Who can get weight loss injections in the UK

The biggest misconception: you need a very high BMI or a diabetes diagnosis

Most people searching this question assume weight loss injections are reserved for people at the extreme end of the BMI scale, or that you need a diabetes diagnosis to qualify. Neither is true. The licensed eligibility criteria in the UK are set by the medicines' regulators based on clinical trial data, and they cover a much wider group.

Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both licensed for adults with a BMI of 30 or above. They are also licensed at a lower threshold (a BMI of 27 or above) for people with at least one weight-related condition. Qualifying conditions include type 2 diabetes, prediabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea and cardiovascular disease, among others. The NHS notes that lower BMI thresholds can apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance, reflecting that the health risks associated with excess weight can arise at a lower BMI in these groups.

What the BMI number does not do is guarantee a prescription. A prescriber looks at the whole picture: your medical history, current medications, any contraindications, and whether either medicine is appropriate for you specifically. Eligibility is a starting point, not a finish line. You can read more about the two licensed options on the weight loss injections overview page.

Who is not suitable for weight loss injections

Knowing who does not qualify is just as useful as knowing who does. Weight loss injections are not recommended for people who are pregnant, breastfeeding, or actively trying to conceive. They are not licensed for anyone under 18. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not use these medicines. A history of pancreatitis or certain gastrointestinal conditions also requires careful prescriber assessment, and in some cases rules treatment out.

The NICE appraisal of tirzepatide (TA1026) also specifies that treatment should be reviewed if less than five percent of body weight is lost after six months at the highest tolerated dose, continuing indefinitely without meaningful response is not the expectation. This is a point worth knowing upfront: these medicines work well for most people in clinical trials, but they are not a guaranteed outcome for every individual.

If you take oral contraceptives, tirzepatide specifically requires an additional non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced. Our page on who can take weight loss injections covers the contraception and HRT considerations in more detail, as does NHS England's guidance on weight management injections.

NHS eligibility versus private eligibility, they are not the same thing

This is where a lot of confusion creeps in. NHS access to tirzepatide is being rolled out in phases through NICE Technology Appraisal 1026, published in December 2024. The current NHS criteria are considerably stricter than the licensed criteria: as of summer 2026, NHS tirzepatide is available only to people with a BMI of 40 or above who have four or more specific weight-related conditions, or those in the BMI 35–39.9 range meeting the same conditions threshold (Cohort 2 activated June 2026). Future phases will gradually widen access, but waiting lists through specialist services are commonly long.

Private eligibility follows the licensed medicine criteria instead, which are the broader BMI 30 / BMI 27-plus-condition thresholds described above. That gap between NHS and private criteria is why many people who are clinically suitable (and who would benefit) are exploring private routes. This page on getting the new weight loss injection walks through what a private consultation actually involves, step by step. For context on what private treatment costs relative to what's included, the weight loss treatment overview covers pricing structure honestly.

It is also worth knowing that GP practices can now prescribe tirzepatide under the 2026/27 GP contract, but participation is optional, coverage varies by practice and area. If you are based in the north-east, our weight loss injections Newcastle page explains how local access works and what the private consultation process looks like in that area.

What happens during the eligibility assessment at a private pharmacy

If you decide to go ahead with a private prescription, the process at a regulated pharmacy like ours starts with a free online consultation. A prescriber (a real, GPhC-registered Independent Prescriber, not an automated system) reads your answers the same day. As part of that review, your identity is verified by photo ID and your current weight is confirmed on a video call. This matters because dosing is based on verified weight, and because the rules around dose increases require evidence of response.

The prescriber checks your medical history, current medications and any contraindications. They may also notify your GP in line with GPhC guidance. If treatment is clinically appropriate, your prescription is issued and your medication is dispatched the same day (for orders placed before 12pm Monday to Friday), arriving with DPD the following working day in plain packaging. If treatment is not appropriate, you will be told clearly why.

The guide on how to get weight loss injections sets out the full process. You can also explore the NHS versus private routes in detail if you want to weigh up both before deciding. Our clinical team's approach is described on the clinical team page. If you have specific questions before starting, the FAQs cover the most common ones. NICE's appraisal of tirzepatide (TA1026) sets out the full clinical recommendation if you want to read the official criteria directly.

Ready to find out if you qualify? Check your eligibility with a free consultation, there is no obligation and no fee for the assessment itself.